Replimune Group (REPL) to Release Earnings on Thursday

Key Points

• Replimune Group is set to announce its Q1 2026 earnings on Thursday, August 14th, with analysts predicting an EPS of ($0.85).
• The company's stock has experienced significant volatility, with a 52-week range of $2.68 to $17.00, and it opened at $5.50 on Thursday.
• Insiders have sold a total of 74,907 shares of Replimune stock worth $603,655 over the last ninety days, indicating a decrease in their position.

Replimune Group (NASDAQ:REPL - Get Free Report) is expected to issue its Q1 2026 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.10). On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Replimune Group Stock Down 0.4%

Shares of Replimune Group stock traded down $0.02 on Thursday, hitting $5.48. 5,850,051 shares of the company's stock traded hands, compared to its average volume of 23,838,406. Replimune Group has a 52-week low of $2.68 and a 52-week high of $17.00. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.17. The stock has a market cap of $426.40 million, a P/E ratio of -1.79 and a beta of 0.67. The firm's 50-day moving average is $8.77 and its 200 day moving average is $9.94.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 3,749 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $30,179.45. Following the sale, the insider directly owned 128,296 shares in the company, valued at $1,032,782.80. This trade represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Philip Astley-Sparke sold 32,279 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total value of $260,168.74. Following the completion of the transaction, the director directly owned 1,405,071 shares of the company's stock, valued at $11,324,872.26. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock valued at $603,655 over the last three months. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares during the period. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock valued at $11,927,000 after acquiring an additional 33,574 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on REPL shares. Barclays lowered shares of Replimune Group from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $17.00 to $3.00 in a report on Wednesday, July 23rd. Cantor Fitzgerald upgraded Replimune Group from a "neutral" rating to an "overweight" rating in a research note on Wednesday, July 30th. HC Wainwright cut Replimune Group from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 23rd. Leerink Partnrs lowered Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Finally, Leerink Partners reiterated a "market perform" rating and issued a $3.00 price target (down from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $7.67.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.